IRIS
RENI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 8.943
EU - Europa 8.793
NA - Nord America 7.571
SA - Sud America 2.615
Continente sconosciuto - Info sul continente non disponibili 558
AF - Africa 197
OC - Oceania 10
Totale 28.687
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.131
RU - Federazione Russa 5.271
SG - Singapore 2.986
CN - Cina 2.770
BR - Brasile 2.173
IT - Italia 1.127
HK - Hong Kong 1.101
VN - Vietnam 988
SE - Svezia 841
FR - Francia 455
BD - Bangladesh 419
DE - Germania 308
GB - Regno Unito 219
CA - Canada 208
AR - Argentina 183
IN - India 169
FI - Finlandia 148
MX - Messico 112
NL - Olanda 91
ZA - Sudafrica 81
EC - Ecuador 78
ID - Indonesia 78
PL - Polonia 72
JP - Giappone 58
IQ - Iraq 55
CO - Colombia 48
AT - Austria 45
ES - Italia 45
TR - Turchia 44
IE - Irlanda 43
PY - Paraguay 36
VE - Venezuela 34
PK - Pakistan 33
UA - Ucraina 31
CL - Cile 29
MA - Marocco 28
AE - Emirati Arabi Uniti 22
EG - Egitto 22
JM - Giamaica 22
MY - Malesia 22
UZ - Uzbekistan 22
CR - Costa Rica 19
PE - Perù 18
KE - Kenya 16
IL - Israele 15
AL - Albania 14
NP - Nepal 14
SA - Arabia Saudita 14
TN - Tunisia 14
LT - Lituania 13
HN - Honduras 12
PH - Filippine 12
TH - Thailandia 12
AZ - Azerbaigian 11
CZ - Repubblica Ceca 11
BB - Barbados 10
BH - Bahrain 10
DZ - Algeria 10
IR - Iran 10
JO - Giordania 10
KZ - Kazakistan 10
LB - Libano 10
NI - Nicaragua 10
KR - Corea 9
AU - Australia 8
BE - Belgio 8
SV - El Salvador 8
EU - Europa 7
GT - Guatemala 7
OM - Oman 7
PR - Porto Rico 7
PS - Palestinian Territory 7
TT - Trinidad e Tobago 7
UY - Uruguay 7
BO - Bolivia 6
CI - Costa d'Avorio 6
MD - Moldavia 6
RO - Romania 6
BY - Bielorussia 5
DO - Repubblica Dominicana 5
PA - Panama 5
PT - Portogallo 5
HU - Ungheria 4
NG - Nigeria 4
QA - Qatar 4
XK - ???statistics.table.value.countryCode.XK??? 4
BG - Bulgaria 3
BS - Bahamas 3
CH - Svizzera 3
CY - Cipro 3
KW - Kuwait 3
LV - Lettonia 3
SN - Senegal 3
YE - Yemen 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
BZ - Belize 2
ET - Etiopia 2
GA - Gabon 2
Totale 28.101
Salva come PNG Salva come JPEG
Città #
Moscow 1.281
Singapore 1.269
Dallas 1.261
Hong Kong 1.090
Ashburn 775
San Jose 617
Shanghai 479
Council Bluffs 465
Hefei 420
Ho Chi Minh City 367
Lauterbourg 367
Princeton 343
Lawrence 342
Beijing 298
Santa Clara 261
New York 257
Milan 211
São Paulo 201
Hanoi 199
Los Angeles 148
Rome 125
Helsinki 100
Boardman 84
Nuremberg 82
Munich 73
Rio de Janeiro 71
Orem 69
Warsaw 62
Chicago 59
Seattle 55
Mexico City 49
Montreal 48
Boston 47
Johannesburg 46
London 46
Belo Horizonte 45
Tokyo 43
Buffalo 42
Dublin 42
Guangzhou 42
Haiphong 42
Phoenix 40
Denver 39
Atlanta 38
Campinas 38
Chennai 38
Cesano Boscone 37
Naples 37
Poplar 37
Toronto 36
Da Nang 35
Houston 35
Stockholm 34
Turku 34
Brooklyn 33
Brasília 32
Porto Alegre 32
Biên Hòa 28
Dhaka 28
Manchester 28
Miami 28
Quito 27
Frankfurt am Main 26
The Dalles 26
Amsterdam 25
Bologna 25
Brescia 25
Mumbai 25
Tianjin 25
Washington 25
Curitiba 24
Hangzhou 24
Guayaquil 23
Tashkent 21
Guarulhos 20
Barnet 18
Changsha 18
Hải Dương 18
San Francisco 18
Shenzhen 18
Vienna 18
Ankara 17
Asunción 17
Caxias do Sul 17
Las Vegas 17
Philadelphia 17
Turin 17
Baghdad 16
Columbus 16
Goiânia 16
Ribeirão Preto 16
Bogotá 15
Catania 15
Charlotte 15
Osasco 15
Can Tho 14
Florence 14
Genoa 14
Juiz de Fora 14
Lappeenranta 14
Totale 13.355
Salva come PNG Salva come JPEG
Nome #
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience 235
Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Combination 211
Postoperative Outcomes and Functional Recovery After Preoperative Combination Chemotherapy for Pancreatic Cancer: A Propensity Score-Matched Study 199
Endoscopic ultrasound-guided choledochoduodenostomy versus hepaticogastrostomy combined with gastroenterostomy in malignant double obstruction (CABRIOLET_Pro): A prospective comparative study 194
Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM) 178
A multicenter study of treatment of primary CNS lymphoma 166
(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial 159
EUS-guided GastroEnterostomy for management of malignant Gastric Outlet Obstruction: a prospective cohort study with matched comparison with Enteral Stenting 158
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). 157
Linee guida AIOM per le neoplasie cerebrali. 157
Ependymoma 157
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma 156
Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment - Risk factors analysis 152
An integrated clinical pathway for pancreatic and periampullary tumor management within the Pancreas Unit network in Lombardy, Italy 151
Communication, understanding and engagement of patients with pancreatic cancer at time of diagnosis 149
A Comprehensive Characterization of Stemness in Cell Lines and Primary Cells of Pancreatic Ductal Adenocarcinoma 149
A four-step method to centralize pancreatic surgery, accounting for volume, performance and access to care 140
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial 140
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants 137
Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives 137
A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer 135
A MULTICENTER TRIAL ASSESSING FEASIBILITY AND EFFICACY OF A COMBINATION OF HIGH-DOSE METHOTREXATE, CYTARABINE AND THIOTEPA IN PATIENTS WITH PRIMARY CNS LYMPHOMA: IMPACT ON OUTCOME OF CYTARABINE DOSE 135
A preoperative score to predict early death after pancreatic cancer resection 135
Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma 134
DIAGNOSTIC DELAY AT DIAGNOSIS AND TIME-TO-TREATMENT INFLUENCE OVERALL SURVIVAL OF PANCREATIC CANCER PATIENTS 128
A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants 126
A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile 126
Diagnostic and therapeutic management of neuroendocrine lung tumors. A clinical study of 44 cases 125
Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapy 123
A multicenter study of the prognosis and treatment of adult brain ependymal tumors 123
A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy 120
Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol 119
Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy 119
Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma 118
ASO Visual Abstract: Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: Proof of Concept for a "Biologic R2 Definition" 117
A randomized phase II trial of adjuvant chemotherapy with cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG regimen) or gemcitabine alone after curative resection for pancreatic cancer 115
Anatomically resectable versus biologically borderline resectable pancreatic cancer definition: refining the border beyond anatomical criteria and biological aggressiveness 114
The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma 114
Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial 113
A phase II trial of second-line therapy with trabectedin in metastatic pancreatic adenocarcinoma 113
ASO Visual Abstract: The Impact of CT-Assessed Liver Steatosis on Postoperative Complications After Pancreaticoduodenectomy for Cancer 111
The Impact of CT-Assessed Liver Steatosis on Postoperative Complications After Pancreaticoduodenectomy for Cancer 111
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial 111
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients 111
A MULTICENTER RETROSPECTIVE STUDY OF CHEMOTHERAPY IN ADULTS WITH EPENDYMOMA. GICNO (GRUPPO ITALIANO COOPERATIVO NEURO-ONCOLOGIA) 111
COMMUNI.CARE (COMMUNIcation and Patient Engagement at Diagnosis of PAncreatic CAncer): Study Protocol 109
A phase II trial of PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced gallbladder, biliary tract, and ampulla of Vater adenocarcinoma, preliminary results 108
A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients 108
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: Results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial 106
Corneal and Epidermal Nerve Quantification in Chemotherapy Induced Peripheral Neuropathy 105
Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma 104
A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia 104
EUS-guided gallbladder drainage and subsequent peroral endoscopic cholecystolithotomy: A tool to reduce chemotherapy discontinuation in neoplastic patients? 103
Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma 103
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial 103
A RANDOMIZED PHASE II TRIAL OF TWO DIFFERENT FOUR DRUG COMBINATIONS IN ADVANCED PANCREATIC ADENOCARCINOMA: CISPLATIN, CAPECITABINE, GEMCITABINE PLUS EITHER EPIRUBICIN OR DOCETAXEL 103
Quaderni dell’infermiere-Neurologia III edizione 103
Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial 102
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies 102
Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence 102
Prediction of early distant recurrence in upfront resectable pancreatic adenocarcinoma: A multidisciplinary, machine learning-based approach 102
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey 101
Efficacy of endoscopic ultrasound-guided ablation with the hybridtherm probe in locally advanced or borderline resectable pancreatic cancer: A phase ii randomized controlled trial 101
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle? 100
RNA Extraction from Endoscopic Ultrasound-Acquired Tissue of Pancreatic Cancer Is Feasible and Allows Investigation of Molecular Features 99
3D conformal radiotherapy significantly reduces toxicity of post-prostatectomy adjuvant or salvage irradiation 99
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer 98
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes 97
Adjuvant Chemoradiation in Pancreatic Cancer: A Pooled Analysis in Elderly (≥75 years) Patients 96
ENDOSCOPIC ULTRASOUND-GUIDED HYBRID THERM ABLATION (EUS-HTP) IN PATIENTS (PTS) WITH LOCALLY ADVANCED (LA) PANCREATIC DUCTAL ADENOCARCINOMA (PDAC): A CASE-CONTROL COMPARATIVE SURVIVAL ANALYSIS 96
Clinical signature and pathogenetic factors of diabetes associated with pancreas disease (T3cDM): a prospective observational study in surgical patients 95
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study 95
Adjuvant PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) or Gemcitabine Followed by Chemoradiation in Pancreatic Cancer: A Randomized Phase II Trial 95
Landscape of Health-Related Quality of Life in Patients with Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review 94
Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients 94
Prognosis of Upfront Surgery for Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies 94
Lessons and open questions in borderline resectable pancreatic cancer 93
Necrosis volume and Choi criteria predict the response to endoscopic ultrasonography-guided HybridTherm ablation of locally advanced pancreatic cancer 92
Evolving pancreatic cancer treatment: From diagnosis to healthcare management 92
Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: Proof of Concept for a “Biological R2 Definition” 92
Isolated lung metastases from pancreatic ductal adenocarcinoma (PDAC): Diagnostic and therapeutic challenges of a different disease 91
A retrospective analysis of postradiation chemotherapy in 133 patients with glioblastoma multiforme 91
The impact of nutritional status on pancreatic cancer therapy 90
Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe 90
Adjuvant chemotherapy in ductal adenocarcinoma of pancreas: a comparison among three regimens 90
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 90
Survival analysis of the metastatic cohort of Italian Association of Medical Oncology (AIOM) GARIBALDI survey. 90
Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma 89
A retrospective series of upfront therapy in primary brain lymphomas 89
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients 89
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer 88
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas 88
Therapeutic management of refractory or relapsed primary central nervous system lymphomas 88
Neoadjuvant chemoradiotherapy in patients with esopageal or esophageal gastric junction cancer 87
Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy (GARIBALDI) 85
Erratum: Time course of hypothalamic-pituitary deficiency in adults receiving cranial radiotherapy for primary extrasellar brain tumors (Radiotherapy and Oncology 99 (2011) (23-28)) 85
Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas 85
Nomogram for Estimating Overall Survival in Patients with Metastatic Pancreatic Cancer 84
ASO Visual Abstract: Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma 84
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas 84
Totale 11.536
Salva come PNG Salva come JPEG
Categoria #
all - tutte 177.819
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 177.819
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022329 0 0 0 30 10 2 5 232 18 5 8 19
2022/20231.774 786 437 54 14 13 220 50 92 51 17 23 17
2023/2024871 53 52 88 93 84 132 26 86 23 35 56 143
2024/20255.355 652 118 88 131 165 457 635 453 971 827 397 461
2025/202618.121 1.181 1.384 1.790 2.521 1.239 414 1.370 1.257 4.821 911 562 671
2026/20272.174 1.228 946 0 0 0 0 0 0 0 0 0 0
Totale 28.687